BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology 2021;164:722-36. [PMID: 34534359 DOI: 10.1111/imm.13416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Robak T, Witkowska M, Smolewski P. The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers 2022;14:771. [DOI: 10.3390/cancers14030771] [Reference Citation Analysis]
2 Karel M, Tullemans B, D'italia G, Lemmens T, Claushuis T, Kuijpers M, Cosemans J. The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. Thrombosis Research 2022. [DOI: 10.1016/j.thromres.2022.02.020] [Reference Citation Analysis]
3 Sabnis RW. Novel BTK Inhibitors for Treating Autoimmune Disorders and Cancer. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00143] [Reference Citation Analysis]
4 Brunner C, Betzler AC, Brown JR, Andreotti AH, Grassilli E. Editorial: Targeting Bruton Tyrosine Kinase. Front Cell Dev Biol 2022;10:909655. [DOI: 10.3389/fcell.2022.909655] [Reference Citation Analysis]
5 McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology 2021;164:722-36. [PMID: 34534359 DOI: 10.1111/imm.13416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Szklener K, Michalski A, Żak K, Piwoński M, Mańdziuk S. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions. Cells 2022;11:1338. [DOI: 10.3390/cells11081338] [Reference Citation Analysis]
7 Deveci B, Saba R. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports. Medicine (Baltimore) 2021;100:e28470. [PMID: 34967391 DOI: 10.1097/MD.0000000000028470] [Reference Citation Analysis]
8 Wolska-Washer A, Robak T. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert Rev Hematol 2022. [PMID: 35296194 DOI: 10.1080/17474086.2022.2054800] [Reference Citation Analysis]